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The isotope-coded affinity tag (ICAT) [1] technology enables the concurrent identification and
comparative quantitative analysis of proteins present in biological samples such as cell and
tissue extracts and biological fluids by mass spectrometry. The initial implementation of this
technology was based on microcapillary chromatography coupled on-line with electrospray
ionization tandem mass spectrometry. This implementation lacked the ability to select proteins
for identification based on their relative abundance and therefore to focus on differentially
expressed proteins. In order to improve the sample throughput of this technology, we have
developed a two-step approach that is focused on those proteins for which the abundance
changes between samples: First, a new software program for the automated quantification of
ICAT reagent labeled peptides analyzed by microcapillary electrospray ionization time-of-
flight mass spectrometry determines those peptides that differ in their abundance and second,
these peptides are identified by tandem mass spectrometry using an electrospray quadrupole
time-of flight mass spectrometer and sequence database searching. Results from the applica-
tion of this approach to the analysis of differentially expressed proteins secreted from
nontumorigenic human prostate epithelial cells and metastatic cancerous human prostate
epithelial cells are shown. (J Am Soc Mass Spectrom 2001, 12, 1238–1246) © 2001 American
Society for Mass Spectrometry
The ability to identify the gene products expressedby a particular cell, tissue or entire organism andto quantify changes in their expression levels
resulting from external (e.g., environmental, pharmaco-
logical) or internal (e.g., genetic, developmental) pertur-
bations is essential to the functional analysis of biolog-
ical systems. Additionally, the quantitative analysis of
gene expression is a valuable diagnostic tool to distin-
guish between cell types [2–6], and to differentiate
between states (e.g., metabolic, activation, pathological)
of a particular cell type [6–8]. These approaches have
all been based on the measurement of mRNA abun-
dances to determine the levels of gene expression. The
motivations for measuring gene expression at the pro-
tein level include the advantage of directly analyzing
the biological effector molecules which can be directly
targeted by drug-based therapeutics, the characteriza-
tion of protein modifications, as well as the accumulat-
ing evidence that the abundances of proteins in many
cases do not correlate with the abundances of their
corresponding mRNA transcripts [9]. Mass spectro-
metry (MS) has proven to be the most effective method
for the identification of proteins in complex samples
[10–13], and recently, MS-based approaches to deter-
mine quantitative profiles of complex protein mixtures
have been developed that employ stable isotope label-
ing of proteins [1, 14–18]. We have developed one such
method which involves the specific, post-isolation la-
beling of proteins on cysteine residues using a biotin-
ylated isotope-coded affinity tag (ICAT, Applied Bio-
systems, Foster City, CA) [1] reagent. Proteins
contained in lysates of cells or tissues representing two
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different biological conditions, or fractions thereof, are
labeled with either an isotopically light version [d(0)] of
the ICAT reagent that contains only hydrogen atoms on
its carbon backbone, or the isotopically heavy version
[d(8)] of the reagent, containing eight deuterium atoms
on its carbon backbone. The protein mixtures are then
combined, digested with the enzyme trypsin, and the
ICAT reagent labeled peptides are isolated by avidin
affinity chromatography using the biotin group on the
reagent as an affinity tag. The peptide mixtures are then
further separated by reverse-phase microcapillary liq-
uid chromatography (RP-LC) [19] with on-line analy-
sis of the eluting peptides by electrospray ionization
(ESI) MS or ESI tandem mass spectrometry (MS/MS).
As the isotopically labeled peptides of the same se-
quence from the two samples are chemically identical,
they behave similarly in subsequent separation and
purification manipulations and are detected concur-
rently by the mass spectrometer. Pairs of peptides of
identical sequence but labeled with the isotopically
different ICAT reagents therefore serve as ideal mutual
internal standards. The signal intensity of the respective
isotopically labeled peptides detected in the mass spec-
trometer is therefore a direct measurement of the rela-
tive level of abundance of the protein from which the
peptide was derived. The measurement of the ratio of
the signals of the d(0) and d(8) labeled forms of all the
peptides detected therefore establishes a quantitative
profile of the proteins contained in the samples compared.
In our initial implementation of the ICAT approach,
we determined the amino-acid sequence of the peptides
present in the samples. This was done on an RP-LC-
ESI-MS/MS system by selecting peptides at specific
mass-to-charge (m/z) values for collision-induced disso-
ciation (CID) [20, 21] using a data-dependent software
routine with dynamic exclusion [22–25]. The acquired
CID were then searched against a peptide sequence
database using the program Sequest, developed at the
University of Washington [26]. In a data-dependent
MS/MS analysis, the mass spectrometer first does a
mass spectral survey scan of all peptides eluting at a
specific point in time from the RP-LC column. The
instrument software then sequentially selects peptides
detected at specific m/z values for CID in descending
order of signal intensity. Each selected m/z value is then
added to an exclusion list so that this peptide will not be
selected for CID again over a set time period. When
using this mass spectrometric approach for the analysis
of ICAT reagent labeled peptides, a routine of alternat-
ing MS and MS/MS scans was used, and the abundance
ratio for each peptide identified by Sequest was then
determined after the mass spectrometric analysis [1].
This initial approach in which protein identification
precedes quantification does not allow the mass spec-
trometer to select peptides for CID analysis based upon
expression ratio. This has two consequences. First, it
results in the identification of many peptides that are
derived from proteins that show no change in abun-
dance between the samples, and most likely are of little
biological interest in the system being studied. This
limits the throughput of the method, as both instrumen-
tal and computational time is consumed analyzing such
peptides. Second, because many peptides coelute dur-
ing the RP-LC separation and the mass spectrometer
preferentially selects the most intense peaks in the mass
spectrum for CID analysis, peptides at low signal inten-
sities are frequently missed. As such peptides are often
derived from low abundance proteins, regulatory
events affecting the abundances of such proteins may
be missed. Many of these low signal intensity peptides
may also be derived from the most biologically inter-
esting, differentially expressed proteins. An additional
limitation of this initial ICAT-based approach was the
lack of an automated software program for quantifying
the ICAT reagent labeled peptide pairs, necessitating
the time-consuming manual determination of the ex-
pression ratios.
Here we describe an advanced method for the anal-
ysis of ICAT reagent labeled peptides that overcomes
some of the analytical limitations of the initial method
described above. The basis of this method is that
quantification precedes protein identification. This
method is schematically illustrated in Figure 1. ICAT
reagent labeled, affinity purified peptide mixtures were
further separated by RP-LC and mass analyzed by
on-line ESI-TOF MS, using post-column flow splitting
such that a portion of the eluent was fraction collected,
and the remaining portion directed into the ESI-TOF
Figure 1. Expression-dependent protein identification strategy.
After labeling of separate protein mixtures with the d(0) and d(8)
forms of the ICAT reagent, respectively, the combined, enzymat-
ically digested, labeled peptides in the mixture are isolated by
avidin affinity chromatography, and further separated by RP-
LC. The eluent from the LC column is post-column flow split,
such that 20% of the flow is directed into an ESI-TOF mass
spectrometer and the remaining portion is collected in one min
fractions in a microtiter plate. The d(0)/d(8) values for the peptide
pairs detected by ESI-TOF MS are then determined using an
automated software routine. Amino acid sequences of peptides
derived from differentially expressed proteins are determined by
MS/MS analysis, by direct infusion of the collected fractions
containing the peptides of interest into an ESI quadrupole TOF
mass spectrometer. Spectra obtained from the MS/MS analysis are
automatically searched against a theoretical protein database to
identify the differentially expressed proteins from which the
selected peptides were derived.
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mass spectrometer. Quantitative analysis of the ICAT
reagent labeled peptides detected by ESI-TOF MS was
done automatically using a novel software routine to
detect peptides derived from proteins which are differ-
entially expressed between the two samples. Next, the
CID spectra of the peptides contained in the collected
fractions which showed differential expression between
the two samples compared were generated in an ESI
quadrupole TOF tandem mass spectrometer (ESI-
QqTOF) [27, 28] and the corresponding proteins were
identified by sequence database searching. We demon-
strate the effectiveness of this approach in the quantifi-
cation of control mixtures of ICAT reagent labeled
proteins, and in the analysis of differentially expressed,
secreted proteins from nontumorigenic and cancerous
human epithelial prostate cells. We also discuss the
potential of this methodology as a general approach to
high-throughput quantitative proteomic analysis.
Experimental Methods
Materials and Reagents
The ICAT (Applied Biosystems, Foster City, CA) re-
agents used were synthesized as previously described
[1]. For all chromatographic steps, HPLC grade aceto-
nitrile (Fisher Scientific), heptafluorobutyric acid
(HFBA) (Aldrich, Milwaukee, WI), acetic acid (Aldrich)
and MilliQ water (Millipore, Bedford, MA) were used.
Analysis of a Control Mixture of ICAT Reagent
Labeled Proteins
Two mixtures containing the same six standard pro-
teins at different concentrations (detailed here as
g/mL Mixture 1, g/mL Mixture 2) were prepared.
The proteins were purchased from Sigma (St. Louis,
MO), and their names are shown along with their
abbreviated names as given in the Swiss-Prot annotated
protein sequence database (http://www.expasy.ch/
sprot/): rabbit glyceraldehyde-3-phosphate dehydroge-
nase (G3P_RABIT) (40,20); E. Coli -galactosidase
(BGAL_ECOLI) (50,50); rabbit phosphorylase b
(PHS2_RABIT) (60,20); chicken ovalbumin
(OVAL_CHICK) (30,60); bovine -lactoglobulin (LACB_
BOVIN) (10,40); bovine -lactalbumin (LCA_BOVIN)
(10,10). The proteins were denatured and reduced to
generate free sulfhydryl groups by treatment with 50
mM Tris buffer, pH 8.5, 6 M guanidine HCl, 5 mM
tributyl phosphine for 1 h at 37 °C. Cysteinyl residues in
each mixture were independently biotinylated with a
fivefold molar excess of either the d(0) or d(8) form of
the ICAT reagent. After combining the two mixtures,
excess ICAT reagent was removed by gel filtration
using Econo-Pac 10 DG columns (Bio-Rad, Richmond,
CA) in 50 mM Tris buffer, pH 8.5 with 0.1% SDS. The
protein mixture was then digested with porcine trypsin
(Promega, Madison, WI) overnight at 37 °C added at a
ratio of 1:50 enzyme:substrate (w/w). The solution was
then passed over a monomeric avidin column (Pierce,
Rockford, IL), prepared following the product instruc-
tions provided by the manufacturer. The column was
washed with water and the biotinylated peptides were
eluted with 0.3% formic acid into fractions of approxi-
mately 1 mL. The LCA_BOVIN sample used in the
dilution experiments was labeled and purified using the
same protocol in a separate reaction.
For the analysis of the six protein standard mixture,
the equivalent of approximately 3 g of total protein of
the digested protein mix were loaded onto a 200 m i.d.
 18 cm fused silica capillary column packed in-house
with Monitor 5 m spherical silica C18 resin of 100 Å
pore size (Column Engineering, Ontario, CA). The
HPLC solvents used consisted of 5% acetonitrile, 0.4%
acetic acid, and 0.005% HFBA in water for Solvent A
and 80% acetonitrile, 0.4% acetic acid, and 0.005%
HFBA in water for Solvent B. A binary gradient from
0–100% B over 30 min was used to elute the peptides
using an Integral HPLC workstation (Applied Biosys-
tems) flowing at 4 L/min across the capillary column.
The eluent was post-column flow split, so that approx-
imately 20% of the flow was directed into a Mariner
ESI-TOF mass spectrometer (Applied Biosystems) and
the remaining flow was diverted for fraction collection.
The time delay of the post-column flow splitter between
the detection of the eluted peptides in the ESI-TOF mass
spectrometer and the collection of the same eluted
peptides in the microtiter plate was measured to be
approximately 15 s. The data was internally calibrated
post-acquisition using the doubly- and singly-charged
states of the strongly detected peptide ALCSEK from
LCA_BOVIN which was known to be contained in the
mixture.
For the control LCA_BOVIN dilution experiments,
the chromatographic system consisted of an Ultimate
nano LC system (LC Packings, San Francisco, CA), a
Famos micro autosampler (LC Packings), and a Swit-
chos II column switching device (LC Packings). 1 L of
sample containing a total of 2 pmol of ICAT reagent
labeled LCA_BOVIN peptides was picked up by the
autosampler and loaded onto a 300 m i.d.  5 mm,
PepMap C18 pre-column (LC Packings) by the loading
pump at a flow rate of 25 L/min. After loading for
approximately 6 min, the pre-column was switched
in-line with a 75 m i.d.  12 cm fused silica capillary
column packed in-house with Monitor 5 m, 300 Å, C18
resin (Column Engineering, Inc. Ontario, CA). The
loaded sample was back-flushed from the precolumn
onto the analytical column at a flow rate of 400 nL/min,
and the peptides were eluted directly into the Mariner
ESI-TOF mass spectrometer using a binary gradient of
0–35% Solvent B performed in 35 min, followed by
100% Solvent B in 4 min and 100% Solvent A in 4 min.
Solvents A and B were as described above. The above
procedure, including injection, valve switching, and
gradient flow, was fully automated using Ultichrom
software (LC Packings).
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Analysis of Secreted Proteins from Human
Prostate Cells
Nontumorigenic parental human prostate cells (P69)
and cells from a highly tumorigenic prostate sub-line
(M12) were grown in serum-free media RPMI-1640
supplemented with epidermal growth factor (EGF) at
10 ng/ml, dexamethasone (0.1 M), bovine insulin,
human transferrin, and selenious acid (ITS, insulin 5
g/ml, transferrin, 5 g/ml, selenium 5 ng/ml) as
described [29]. Secreted proteins from P69 and M12
cells were isolated by concentrating serum free cell
conditioned media using a 5000 MW cutoff membrane
(Amicon, Bedford, MA). 100 g each of P69 and M12
secreted proteins were labeled with d(0) or d(8) ICAT
reagent, respectively, as described above for the stan-
dard proteins. Labeled proteins were mixed, digested
with trypsin at a ratio of 1:50 enzyme:substrate (w/w),
and trypsin was inactivated by boiling the sample for 5
min followed by the addition of an inhibitor (PMSF).
Digested ICAT reagent labeled peptides were purified
by binding to a 500 L slurry of immobilized strepta-
vidin (Pierce, Rockford, IL), and eluted by heating at
65 °C for 30 min in 100% methanol.
Approximately 8 g of total ICAT reagent labeled
prostate proteins was loaded onto a RP-LC column
and the peptides were eluted using a binary gradient
from 15–50% Solvent B over 85 min using the same
RP-LC conditions and post-column flow splitting
set-up as described above. The eluent was manually
fraction collected in one-min time intervals into a low
peptide affinity Nunc Microwell (Fisher Scientific,
Rockford, IL) microtiter plate. The collected fractions
were allowed to air dry. The acquired data was inter-
nally calibrated post-acquisition using a strongly de-
tected transferrin peptide known to be present in the
mixture.
Automated Quantification of Detected Peptides
ICAT reagent labeled peptides eluted from the RP-LC
columns and detected by ESI-TOF MS were automati-
cally quantified using an ICAT reagent specific software
program. The program first detects the peaks from 20
summed spectra (spanning 40 s of elution time),
decharges multiply charged components, and deiso-
topes isotope clusters, producing a list of monoisotopic
masses. This summation is repeated every 10 spectra, so
that each spectrum is counted twice. In all cases peak
detection sensitivity was set at 2% of the most intense
peak (base peak) detected over the entire RP-LC run.
Next, the nearly identical masses from adjacent or
nearly adjacent spectra are combined. This bundling
process calculates an intensity-weighted average mass
for all calculated monoisotopic masses within 100 ppm
of each other from the adjacent spectra. For each of the
bundled masses, the intensities from all adjacent spectra
are summed and the charge state of the most intense
component is stored along with the intensity-weighted
spectrum number of the detected mass in the acquired
mass chromatogram, the upper and lower bounds of
the spectra that were combined, and the number of
individual components that were combined to generate
the mass bundle. Finally, the bundle list of masses is
searched for components which differ by exactly the
expected difference of 8.05 Da (or 16.1 Da for peptides
containing two cysteines) between the d(0) and d(8)
labeled peptides. These clusters are placed into a sepa-
rate table, and the d(0)/d(8) values are calculated for
these peptide pairs as well as the deviation in ppm of
the cluster from the expected mass difference between
the labeled peptides. For all samples analyzed here, the
d(0)/d(8) values were calculated for only those peptide
pairs showing a deviation of 10 ppm or less from this
expected mass differential.
Protein Identification by ESI Quadrupole TOF
MS/MS
After analysis by ESI-TOF MS and automated quantita-
tive analysis using the software program described
above, ICAT reagent labeled peptides from the prostate
samples determined to have at least a twofold differ-
ence in expression were selected for MS/MS analysis.
The fractions containing the peptides of interest were
redissolved in 2 L of 50% acetonitrile containing 0.1%
acetic acid. The solution was then directly infused into
an ESI QqTOF mass spectrometer (MDS Sciex, Concord,
Ontario, Canada) at a flow rate of approximately 300
nL/min. The TOF detector was initially externally cal-
ibrated by infusing a standard peptide mixture, result-
ing in a mass accuracy of approximately 50 ppm when
analyzing the collected fractions. During the infusion of
each fraction an initial mass spectrum was acquired to
confirm the presence of the peptides to be selected for
MS/MS analysis. The instrument was then switched
into MS/MS mode and the m/z value of each peptide of
interest was selected for CID by the analytical quadru-
pole using an approximately 3 Da wide mass window.
Nitrogen was used as a cooling gas in the analytical
quadrupole and as a collision gas in the collision cell.
For each precursor ion, the collision energy determined
by the potential difference between the analytical quad-
rupole and the collision cell was initially set at approx-
imately 30 volts. This potential difference was gradually
increased to obtain a desired degree of fragmentation.
Amino acid sequences of the selected peptides were
automatically identified by sequence database search-
ing of the MS/MS spectra using the Sequest software.
CID mass spectra from the human prostate samples
were searched against an annotated database contain-
ing approximately 75,000 human proteins compiled at
the Frederick Biomedical Supercomputing Center,
Frederick, MD. The mass window for the single-
charged molecular ion of the precursor peptide was
given a tolerance of 0.05 Da deviation between the
measured monoisotopic mass and the calculated mo-
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noisotopic mass. Additionally, the database search was
constrained to only those peptide sequences containing
a cysteine residue. Only those peptides receiving a
correlation score greater than 2.0 or a delta correlation
score of greater than 0.2 in the Sequest analysis [26]
were considered as potential positive identifications.
Results and Discussion
Automated Quantification of ICAT Reagent
Labeled Peptides
ICAT reagent labeled peptides eluted from the RP-LC
columns and detected by ESI-TOF MS were automati-
cally quantified using a novel ICAT reagent specific
software program that is described above in detail. Such
an automated software routine is essential to the devel-
opment of any high-throughput quantitative proteomic
analysis approach, as manual interpretation of mass
spectral data from complex ICAT reagent labeled mix-
tures is prohibitively time consuming. The program
described here relies on the high mass accuracy and
mass resolution afforded by TOF detection, which en-
ables the accurate and unambiguous quantitative anal-
ysis of ICAT reagent labeled peptides without prior
knowledge of their amino acid sequence. In order to test
the effectiveness of the automated software program for
quantifying ICAT reagent labeled peptides from ESI-
TOF MS data, a mixture of control proteins was first
analyzed. This mixture contained six proteins, with
each protein having been labeled separately with the
d(0) and d(8) version of the ICAT reagent, respectively.
The d(0) and d(8) labeled mixtures of each protein were
then combined at the ratios indicated (see Experimental
Methods and Table 1), enzymatically digested, and the
labeled peptides were purified using avidin affinity
chromatography. This mixture was then analyzed by
RP-LC ESI-TOF MS and quantified using the auto-
mated quantification software in order determine the
Table 1. Automated quantitative analysis results of a control protein mixture
Protein
[expected
d(0)/d(8)]a Peptide sequence
(MH)
calculated
(MH)
measured
Abs. error
(ppm) d(0)/d(8)
BGAL_ECOLI C*QLAQVAER 1531.798 1531.775 14.8 1.3
(1.0) C*SHYPNHPL 1581.758 1581.753 3.0 1.2
LSLPGETRPLILC*EYA 2289.224 2289.233 4.0 1.3
C*GTR 950.480 950.484 4.2 1.3
Avg: 1.3  0.05
PHS2_RABIT FGC*R 996.501 996.507 5.8 0.4
(0.33) C*NPGLAEIIAER 1799.940 1799.941 0.6 0.4
LVLC*NPGLAEIIAER 2125.177 2125.165 5.6 0.4
Avg. 0.40  0.00
OVAL_CHICK YPILPEYLQC*VK 1980.059 1980.044 7.4 2.5
(2.0) C*VSP 919.463 919.469 6.0 2.5
Avg. 2.50  0.00
G3P_RABIT VPTPNVSVVDLTC*R 2014.072 2014.060 6.1 0.5
(0.50) VSVVDLTC*R 1505.807 1505.802 3.3 0.6
Avg. 0.55  0.07
LACB_BOVIN LSFNPTQLEEQC*HI 2173.067 2173.058 4.2 3.7
(4.0) C*MENSAEPEQSL 1851.806 1851.808 1.1 3.1
Avg. 3.4  0.40
LCA_BOVIN C*EVFR 1167.591 1167.593 1.5 1.0
(1.0) IWC*K 1063.569 1063.573 4.3 1.0
ALC*SEK 1164.601 1164.602 1.0 1.0
Avg: 1.0  0.00
a The expected d(0)/d(8) values for each of the six proteins contained in the control mixture are shown below each protein name. The calculated
protonated, single-charged molecular ion mass of the only the d(0) labeled peptide for each peptide pair is shown, along with measured value as
calculated by the quantification program from the ESI-TOF mass spectrometric data. The C* in each peptide sequence indicates the d(0) labeled
cysteine residue. Only the d(0) peptide mass for each detected ICAT reagent labeled pair was calculated and outputted by the automated program.
The average d(0)/d(8) value for the peptides detected from each protein is shown, along with the standard deviation between these values.
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accuracy of this program. The results are shown in
Table 1. As this mixture of proteins produced a limited
number of peptides when digested using trypsin, the
detected peptides were identified by matching the
highly accurate masses detected by ESI-TOF MS with
the peptide masses known to be present in the mixture.
It should be noted that there was an unusual number of
non-specifically cleaved peptides present in this sample
(e.g.,, the peptides found for LACB_BOVIN), and the
identity of these peptides was initially determined by
MS/MS analysis of the control mixture using an ion-
trap mass spectrometer (data not shown). The results
shown in Table 1 demonstrated the high precision of
this automated quantitative program, as the average
standard deviation in d(0)/d(8) values measured for
different peptides derived from the same protein was
approximately 0.09 for the standard proteins. Addi-
tionally, the average absolute error between the ex-
pected and measured d(0)/d(8) values for each protein
was approximately 16% for these six proteins. These
errors may be due at least in part to sample handling
and pipetting errors introduced in the preparation of
these standard proteins.
Next, in order to test the dynamic range over which
the automated quantification program was applicable, a
dilution series containing d(0) and d(8) labeled forms of
the protein bovine -lactalbumin (LCA_BOVIN) was
prepared. The ratios tested were (d(0):d(8)) 1:1, 2:1, 4:1,
and 10:1. The samples were analyzed in three indepen-
dent experiments by RP-LC ESI-TOF MS, and quanti-
fied using the automated quantification program. Four
cysteine containing, tryptically digested peptides from
LCA_BOVIN were detected and the d(0)/d(8) values of
these peptide pairs were averaged in three runs to give
a final d(0)/d(8) value for the protein at each point in
the dilution series. The results are presented in Figure 2.
The observed d(0)/d(8) values are plotted against the
expected values. The correlation between the expected
and observed values was very good, with an R-squared
value of 0.997. The error bars shown represent the
standard deviation of the average d(0)/d(8) values
calculated for the LCA_BOVIN protein between each of
the three runs at each point in the dilution series. It is
apparent that the variability between measurements
increases as the value of d(0)/d(8) increases, with a
standard deviation of 0.05 for an expected d(0)/d(8)
value of 1 increasing to 1.0 for an expected d(0)/d(8)
value of 10. In general, for d(0)/d(8) values of 20 or
higher, the ability to accurately quantify the peptides
was severely compromised, mostly due to the inability
to detect the lower abundance peak which was usually
at or below the noise level in the mass spectrum (data
not shown). In these cases, the amount of the d(8)
labeled peptides was below 100 femtomoles loaded.
Increasing the total amount of d(0) and d(8) labeled
peptides loaded onto the RP-LC would help to in-
crease the accuracy of quantification at these more
extreme d(0)/d(8) values.
Analysis of Differential Protein Expression in
Human Prostate Cells
After determining the effectiveness of the automated
quantification of ICAT reagent labeled control proteins
analyzed by RP-LC ESI-TOF MS, we applied this
methodology to the quantitative analysis of proteins
secreted by nontumorigenic human epithelial prostate
cells and a metastatic, cancerous derivative cell line. 100
g each of secreted proteins from nontumorigenic pa-
rental human prostate cells (P69T), and a highly tumor-
igenic derivative (M12) were isolated from cells cul-
tured in media containing transferrin to stimulate cell
proliferation [30], and these proteins were labeled with
the d(0) and the d(8) forms of the ICAT reagents
respectively. The labeled protein mixtures were com-
bined, digested with trypsin, and the ICAT reagent
labeled peptides purified using avidin–biotin affinity
chromatography. The peptide samples were analyzed
by RP-LC using the setup shown in Figure 1. Post-
column flow splitting was employed, such that20% of
the eluent from the RP-LC column was directed into
the ESI-TOF mass spectrometer at a flow rate of 1
L/min, and the remaining portion was diverted for
manual fraction collection into a microtiter plate. One
min fractions were collected. Automated quantitative
analysis of the ESI-TOF MS data resulted in the identi-
fication of 97 putative pairs of ICAT reagent labeled
peptides. Only those peptides having a molecular
weight greater than 1200 Da were considered in this
analysis, as peptides tagged with the ICAT reagent
[MW  514.3 for the d(0) form] that have molecular
weights less than 1200 Da generally contain too few
amino acids to unambiguously identify the protein
from which it was derived. Additionally, the automated
quantification program was set to only consider those
peptide pairs having a deviation from the expected
mass difference between the d(0) and d(8) labeled
peptides of 10 ppm or less. This constraint takes advan-
tage of the mass accuracy afforded by the ESI-TOF mass
spectrometer (4.6 ppm average absolute error for the
Figure 2. Results from dilution experiments on LCA_BOVIN
control protein. The average d(0)/d(8) values for the control
protein LCA_BOVIN from three independent analyses by ESI-
TOF MS are plotted against the expected values at four different
dilutions. The overall protein d(0)/d(8) value was determined in
each of the three analyses by averaging the d(0)/d(8) values
automatically determined from four cysteine-containing, tryptic
peptides derived from this protein. The correlation coefficient for
this regression was 0.997.
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control peptides in Table 1), which enables a very
accurate determination of ICAT reagent labeled peptide
pairs contained in complex mixtures without prior
knowledge of the amino acid composition of these
peptides.
Of the 97 ICAT reagent labeled peptide pairs initially
identified by the automated program, 33 showed at
least a twofold difference in expression between the two
samples. The masses of this subset of peptides were
then selected for identification by tandem mass spec-
trometry. As both the nontumorigenic and tumorigenic
prostate cells were cultured in media containing an
equal concentration of the protein transferrin to stimu-
late cell proliferation there was a high abundance of
ICAT reagent labeled peptides derived from transferrin
in both of these samples. The d(0)/d(8) values for these
peptides were used as an internal control for the quan-
titative analysis. Therefore, along with the peptides
from differentially expressed proteins, we also chose to
identify a random sampling of peptide pairs showing
strong signal intensities and d(0)/d(8) values of close to
1, assuming that these peptides were derived from
transferrin. For the identification of the peptides, the
fractions containing the peptides of interest were di-
rectly infused into an ESI QqTOF mass spectrometer,
the m/z value of each specific peptide was selected for
CID, and the resulting CID mass spectra were searched
against a peptide sequence database. Due to the highly
accurate measurement of the precursor peptide masses
afforded by the ESI QqTOF mass spectrometer, the
precursor peptide mass window was constrained to
0.05 mass units in the database searches. This mass
constraint has been shown to greatly increase the con-
fidence and speed of database searching for protein
identification [31, 32].
Table 2 shows the proteins identified in this experi-
ment. In all, 17 peptides were identified from the
transferrin protein. The average d(0)/d(8) value for
these was 1.3 with a standard deviation of 0.1, dem-
onstrating the high level of precision of the automated
quantitative analysis program. The value of 1.3 was
slightly higher than the expected value of 1.0 between
the two samples, most likely due to variability in the
initial pipetting and sample handling of the prostate
samples. Therefore, the d(0)/d(8) values for the differ-
entially expressed proteins identified by MS/MS anal-
ysis were normalized against this control value of 1.3.
Six proteins showing at least a twofold difference in
expression from the ESI-TOF mass spectrometric anal-
ysis were identified by MS/MS analysis. The mass
spectral result for the protein identified as SPRC (se-
creted protein rich in cysteine, also known as osteonec-
tin) is shown in Figure 3. The increased expression of
SPRC in cancerous prostate cells has been described
previously [33, 34] and accordingly in our work it
showed almost a fivefold increase in expression in the
cancerous M12 prostate cells. Additionally, both the
glycoprotein A2HS (alpha-2-HS-glycoprotein) [35] and
serum albumin [36] have been shown previously to be
down-regulated in cancerous cells lines, in concordance
with the results shown here. This set of six proteins was
identified from the sequence determination of eight
separate peptides (two peptides were identified from
the proteins SPRC and serum albumin). Attempts to
determine the sequences of other peptides derived from
differentially expressed proteins between the two sam-
Table 2. Identified, differentially expressed proteins from nontumorigenic and cancerous human prostate cells
Protein Name d(0)/d(8)
Transferrin (internal control)a 1.3  0.1
Increased Expression in Cancerous Prostate Cells
SPRC_HUMAN (secreted protein acidic and rich in protein, osteonectin)bc 0.2 (0.2, 0.2)
SODC_HUMAN (superoxide dismutase) 0.4
Decreased Expression in Cancerous Prostate Cells
T34519 (MAPK-activated protein kinase)d 2.0
ALBU_HUMAN (serum albumin precursor)bc 2.4 (2.0, 2.7)
A2HS_HUMAN (alpha-2-hs-glycoprotein precursor, fetuin A)c 4.0
INS_HUMAN (insulin precursor)c 14.2
a The average d(0)/d(8) value for the 17 peptides identified from the internal control transferrin protein is shown, along with the standard deviation
between these peptides. The expected d(0)/d(8) value for this protein was 1.0. The d(0)/d(8) values shown for the differentially expressed proteins
from the prostate cells were normalized to this control value by dividing the measured d(0)/d(8) values by 1.3.
b Two separate peptides were identified from each of these proteins. For these proteins, the average d(0)/d(8) values from these peptides are given,
with measured values for each of the peptides shown in parentheses.
c Peptides for these proteins were also identified independently by RP-LC-ESI-MS/MS analysis using an ion-trap mass spectrometer (data not
shown). The d(0)/d(8) values measured in this separate analysis were also in agreement with those determined in this work. The human insulin
peptide sequence identified here is common to bovine insulin, which was contained in the cell culture media. However, another peptide specific to
human insulin and showing the same d(0)/d(8) value was identified using the ion-trap mass spectrometer, indicating that the differential expression
of insulin was due to cellular effects and not an experimental artifact.
d This protein was identified from the Protein Information Resource database (http://www-nbrf.georgetown.edu/pirwww/pirhome.shtml). All other
proteins shown are from the Swiss-Prot annotated protein database (http://expasy.cbr.nrc.ca/sprot/).
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ples were unsuccessful primarily due to lack of robust
signal intensity in the ESI QqTOF mass spectrometer,
most likely because of the loss of sample from adsorp-
tion of these peptides to the surface of the microtiter
plates upon drying down of the collected fractions.
Keeping the collected peptides in solution prior to
MS/MS analysis may have helped to minimize the loss
of sample.
Conclusions
The ability to select only the most biologically interest-
ing proteins which show significant expression differ-
ences between two samples greatly increases the effi-
ciency of quantitative proteomic analyses, as many
times the majority of expressed proteins are not differ-
entially expressed (in this study 66% of the detected
peptides from the prostate samples showed less than
twofold expression differential). In another study in
which changes in protein abundances were studied
during in vitro differentiation of human HL-60 cells,
approximately 90% of the proteins analyzed showed no
significant change in abundance [37]. We have demon-
strated the effectiveness of an automated quantitative
software routine that enables the selection of these
differentially expressed proteins from complex mix-
tures for amino acid sequence identification. This pro-
gram relies on the mass accuracy and resolution af-
forded by the ESI-TOF mass spectrometer in order to
quantify ICAT reagent labeled peptide pairs without
the need for prior knowledge of the amino acid se-
quence of the peptides. This type of analysis would not
be possible with other mass spectrometers which em-
ploy quadrupole detectors, as these do not generally
provide sufficient mass accuracy and resolution. As a
further point, the mass accuracy of ESI-TOF MS and the
automated quantitative analysis routine described here
could also be used to rapidly and accurately quantify
ICAT reagent labeled peptides that have been initially
identified by MS/MS analysis. In this case, matching
the accurate masses of the quantified peptides detected
by ESI-TOF MS to the masses of the previously identi-
fied peptides would provide a rapid method to inves-
tigate changes in protein expression in dose response,
time course, or other systematic perturbation experi-
ments on a known system of proteins.
The approach we describe here does have some
limitations in its current state. The identification of
peptides derived from differentially expressed proteins
by direct infusion into the ESI QqTOF mass spectrom-
eter is not robust, most likely due to sample losses in the
drying down and transferring of the collected fractions
from the RP-LC column to the mass spectrometer for
MS/MS analysis. These extra sample handling steps in
conjunction with the less sensitive MS/MS analysis by
direct infusion decrease the overall sensitivity of this
approach relative to the initially described method in
which peptides were first identified by RP-LC-ESI-
MS/MS and then quantified [1]. To decrease the sample
loss in the approach described here, rather than drying
down the fractions these could be diluted with the
proper solvent, and loaded onto a RP trapping column,
and eluted directly into the ESI-QqTOF mass spectrom-
eter for identification of selected peptides. Additionally,
the use of the relatively large 200 m i.d. RP-LC
column facilitates greatly increased sample loading
capacity in the initial quantification step by ESI-TOF
MS, at least partially compensating for sample losses in
the subsequent MS/MS analysis steps. Another disad-
vantage to this approach is that it involves the use of
two separate mass spectrometers. It would be beneficial
to carry out both the quantification and identification of
ICAT reagent labeled peptides on one instrument.
However, the slight retention differences between the
d(0) and d(8) labeled peptides [1] precludes on-the-fly
quantification and MS/MS analysis based on relative
peptide abundance levels using existing automated
RP-LC-ESI-MS/MS routines. We have recently de-
scribed an alternative approach using a MALDI quad-
rupole TOF mass spectrometer which does enable both
the quantification and expression-dependent identifica-
Figure 3. Representative results for the identification of a differ-
entially expressed protein from cancerous human prostate epithe-
lial cells. (a) The base peak ion chromatogram from the RP-LC-
ESI-TOF mass spectrometric analysis of ICAT reagent labeled
human prostate proteins is shown. (b) The accumulated mass
spectra summed over the highlighted portion of the ion chromato-
gram is shown, with a circled portion of this mass spectrum which
contains a pair of triple-charged, ICAT reagent labeled peptides
showing differential expression. The inset is a magnification of
this portion of the mass spectrum, where monoisotopic m/z values
from the isotopically-resolved d(0) labeled peptide (from the
nontumorigenic prostate cells) and the d(8) labeled peptide (from
the metastatic cancerous prostate cells) are labeled. As these are
triple-charged species, the m/z difference between the peptides is
2.7 mass units. The automatically determined d(0)/d(8) value
for this pair of peptides was 0.24. (c) The collected fraction
containing this pair of peptides was directly infused into the
ESI-QqTOF mass spectrometer, and the peak at the m/z value of
628.3 was selected for CID. The peptide was identified by database
searching of the CID mass spectrum as being derived from the
human protein SPRC (secreted protein rich in cysteine), a protein
known to show increased expression in cancerous prostate cells.
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tion of peptides using a single instrument that has great
potential for high-throughput analyses [38].
Finally, it has been previously demonstrated [39]
that it may be possible to construct a peptide database
for a specific organism, cell, or tissue type that would
enable the unambiguous identification of proteins iso-
lated from these sources directly from the accurate
measurement of peptide masses, given a sufficient
number of other constraints (e.g., tryptic peptides con-
taining cysteine, hydrophobicity) on the detected pep-
tides. This would obviate the need for MS/MS analysis
and significantly increase the throughput and sensitiv-
ity for quantitative proteomic analysis. The system
described here which couples the mass accuracy of
ESI-TOF MS with automated quantitative analysis
would be an ideally suited analysis platform if a com-
plete database were available, and we are currently
investigating the feasibility of creating such a database.
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